INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
DA

Dandekar Atul

CSBOCIK 0002050167

EDGAR filingsOpen in network
Disclosed transactions46
Buys / sells0 / 18
Max Insider Score36
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
3
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$69K
6,643 sh
Oct 29, 2026Oct 30, 2026
traded Oct 29, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Maze Therapeutics, Inc.CSBO · Dec 31, 2025
0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M
$8,930
857 sh
Oct 29, 2026
Oct 30, 2026
traded Oct 29, 2026
+1d
SEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
857 sh
Oct 29, 2026Oct 30, 2026
traded Oct 29, 2026
+1dSEC FORM 4

Evidence

10
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$241K
7,500 sh
Oct 29, 2026Oct 30, 2026
traded Oct 29, 2026
+1dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,643 sh
Oct 29, 2026Oct 30, 2026
traded Oct 29, 2026
+1dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
7,500 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

10
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$203K
7,500 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

3
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$78K
7,500 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

36
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$83K
3,207 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

36
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$74K
2,800 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

29
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$929
36 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

29
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$11K
391 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

10
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise
M—
12.5K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

2
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise
M—
12.5K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

3
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$78K
7,500 sh
Aug 28, 2026Aug 31, 2026
traded Aug 28, 2026
+3dSEC FORM 4

Evidence

24
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$207K
7,500 sh
Aug 28, 2026Aug 31, 2026
traded Aug 28, 2026
+3dSEC FORM 4

Evidence

4
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
7,500 sh
Aug 28, 2026Aug 31, 2026
traded Aug 28, 2026
+3dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
7,500 sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

3
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$78K
7,500 sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

14
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$210K
7,500 sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

14
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$198K
7,500 sh
May 29, 2026Jun 2, 2026
traded May 29, 2026
+4dSEC FORM 4

Evidence

3
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$78K
7,500 sh
May 29, 2026Jun 2, 2026
traded May 29, 2026
+4dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
7,500 sh
May 29, 2026Jun 2, 2026
traded May 29, 2026
+4dSEC FORM 4

Evidence

17
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise
M$87K
8,320 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

13
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise
M$62K
5,985 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

14
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise
M—
8,320 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

10
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise
M—
5,985 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

9
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$190K
7,500 sh
Apr 29, 2026May 1, 2026
traded Apr 29, 2026
+2dSEC FORM 4

Evidence

7
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$78K
7,500 sh
Apr 29, 2026May 1, 2026
traded Apr 29, 2026
+2dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
7,500 sh
Apr 29, 2026May 1, 2026
traded Apr 29, 2026
+2dSEC FORM 4

Evidence

19
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$196K
6,710 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC FORM 4

Evidence

7
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$78K
7,500 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
7,500 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC FORM 4

Evidence

12
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$24K
790 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC FORM 4

Evidence

18
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$52K
1,200 sh
Jan 29, 2026Feb 2, 2026
traded Jan 29, 2026
+4dSEC FORM 4

Evidence

10
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$78K
7,500 sh
Jan 29, 2026Feb 2, 2026
traded Jan 29, 2026
+4dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
7,500 sh
Jan 29, 2026Feb 2, 2026
traded Jan 29, 2026
+4dSEC FORM 4

Evidence

22
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$126K
2,800 sh
Jan 29, 2026Feb 2, 2026
traded Jan 29, 2026
+4dSEC FORM 4

Evidence

22
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$154K
3,500 sh
Jan 29, 2026Feb 2, 2026
traded Jan 29, 2026
+4dSEC FORM 4

Evidence

26
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$248K
6,035 sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence

11
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$4,036
100 sh
Dec 30, 2025Dec 31, 2025
traded Dec 30, 2025
+1dSEC FORM 4

Evidence

11
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
72.4K sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
100 sh
Dec 30, 2025Dec 31, 2025
traded Dec 30, 2025
+1dSEC FORM 4

Evidence

17
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$754K
72.4K sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence

36
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$2.69M
66.4K sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$1,042
100 sh
Dec 30, 2025Dec 31, 2025
traded Dec 30, 2025
+1dSEC FORM 4

Evidence